A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days
2011

Safety of VivaGel® in Young Women

Sample size: 54 publication 10 minutes Evidence: moderate

Author Information

Author(s): Cohen Craig R., Brown Joelle, Moscicki Anna-Barbara, Bukusi Elizabeth A., Paull Jeremy R. A., Price Clare F., Shiboski Stephen

Primary Institution: University of California San Francisco

Hypothesis

To assess the safety of VivaGel® used vaginally twice daily for 14 days among healthy, sexually-abstinent women, aged 18–24 years in the USA and Kenya.

Conclusion

GU adverse events and colposcopic findings consistent with mild epithelial irritation and inflammation occurred more commonly among women in the VivaGel arm.

Supporting Evidence

  • 83% of participants in the VivaGel arm experienced at least one grade 1 or 2 GU adverse event.
  • No grade 3 or 4 adverse events occurred during the trial.
  • Colposcopic findings were significantly more common in the VivaGel arm compared to placebo.

Takeaway

The study tested a gel called VivaGel® to see if it was safe for young women to use. Some women had mild irritation, but it was mostly safe.

Methodology

Participants were randomized 2:1 to receive either VivaGel or placebo, and safety was assessed by comparing adverse events and colposcopy findings.

Potential Biases

Potential bias due to differences in participant demographics and adherence rates between sites.

Limitations

The study was closed before reaching the planned sample size of 60 participants.

Participant Demographics

Healthy, sexually-abstinent women aged 18-24 from the USA and Kenya.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 0.8-2.2

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016258

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication